NetE Toxin Gene Recombinant Expression for C. perfringens Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding and control measures for Clostridium perfringens-induced enteric diseases in animals, particularly in foals, dogs, and adult horses, are incomplete, with Type A strains causing severe necrotizing and hemorrhagic gastroenteritis, and existing diagnostic and treatment methods are inadequate.
Innovation Solution
Isolation of a novel toxin gene, NetE, and its associated nucleic acids and proteins, along with recombinant expression vectors, fusion proteins, and immunogenic compositions, including antibodies, to develop diagnostic methods and treatments for Type A Clostridium perfringens enteric diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic and treatment methods are used for Type A Clostridium perfringens enteric diseases, then existing knowledge and control measures are applied, but the understanding and control remain incomplete and inadequate
Solution Approach 1:
The patent creates recombinant expression vectors that copy and express the novel NetE toxin gene in host cells, allowing production of the toxin protein for diagnostic purposes. This copying approach enables accurate detection of the toxin without requiring direct detection of the bacterial gene in complex samples.
Solution Approach 2:
The patent uses antibodies as intermediary molecules that bind to the NetE toxin protein. These antibodies serve as mediators between the toxin and detection systems, enabling reliable detection and measurement of the toxin's presence and concentration in animal samples.
2Reliability
If conventional treatment methods are used, then existing therapies are administered, but the treatment effectiveness remains inadequate for severe necrotizing and hemorrhagic gastroenteritis
Solution Approach 1:
The patent converts the harmful NetE toxin into a beneficial diagnostic and therapeutic target by producing recombinant toxin proteins and corresponding antibodies. The toxin that causes disease is now used as a marker for diagnosis and as a target for therapeutic antibodies, transforming the harmful element into a useful tool for control.
Solution Approach 2:
The patent performs preliminary characterization and production of the NetE toxin and its antibodies before clinical application. By pre-producing the recombinant toxin and screening antibody binding properties in advance, the system is prepared for effective diagnostic and therapeutic use when needed.
3Loss of information
If plasmid-based toxin genes are characterized, then virulence mechanisms are better understood, but the complexity of pathogenicity loci increases
Solution Approach 1:
The patent extracts and isolates the specific netE gene from the complex plasmid-borne pathogenicity locus. By taking out only the relevant toxin gene and its immediate regulatory elements, the system simplifies the genetic complexity while maintaining the essential virulence information needed for characterization and diagnosis.
Data Source
AI summary
The present disclosure relates to a novel toxin of Type A C. perfringens and immunogenic compositions and vaccines thereof. The present disclosure further relates to methods and uses of treating or preventing enteric disease and assays for diagnosing enteric disease in mammals.